8-K: Cellectar Biosciences Announces 2024 Financial Results and Regulatory Alignment for Waldenström Macroglobulinemia Treatment

Cellectar Biosciences reports its 2024 financial results, highlights regulatory progress for its lead drug candidate, iopofosine I 131, and outlines plans for upcoming clinical trials.

Summary

• Cellectar Biosciences announced its financial results for the year ended December 31, 2024, and provided a corporate update on March 13, 2025.
• The company achieved alignment with the FDA on a regulatory path for potential accelerated approval of iopofosine I 131 for Waldenström macroglobulinemia (WM).
• Cellectar is evaluating the timing for Phase 1 solid tumor studies and plans to submit an IND for an alpha-emitting radioconjugate.
• The company's cash and cash equivalents as of December 31, 2024, were $23.3 million, compared to $9.6 million as of December 31, 2023.
• R&D expenses for 2024 were approximately $26.1 million, compared to $27.3 million in 2023.
• G&A expenses for 2024 were approximately $25.6 million, compared to $11.7 million in 2023.
• The net loss for the full year ending December 31, 2024, was $44.6 million, or $1.22 per basic share and $1.40 per diluted share.
• The company expects to complete full patient enrollment within 24 months of the first patient admitted to the study for iopofosine I 131.
• The total study cost for iopofosine I 131 is expected to be between $40M-$45M, with approximately $30M to full enrollment.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. Positive aspects include FDA alignment, promising clinical data, and sufficient cash runway. However, the net loss and increased G&A expenses temper the overall sentiment.

Positives

• FDA alignment on regulatory path for iopofosine I 131 accelerates potential approval for WM treatment.
• Strong clinical data from the Phase 2 CLOVER-WaM study supports the efficacy and safety of iopofosine I 131.
• The company has sufficient cash to fund operations into the fourth quarter of 2025.
• The company is advancing its pre-clinical radioconjugate assets, CLR 121225 and CLR 121125, to support Phase 1 solid tumor studies.
• The company is evaluating inbound inquiries regarding a range of collaborations for iopofosine I 131, which it views as an attractive, non-dilutive funding approach.

Negatives

• The company reported a net loss of $44.6 million for the year ended December 31, 2024.
• General and administrative expenses increased significantly to $25.6 million in 2024, driven by costs associated with potential commercialization infrastructure.

Risks

• The company's ability to raise additional capital is uncertain.
• The company is dependent on its sole source supplier of iopofosine.
• Drug development involves a high degree of risk, including uncertainties related to patient enrollment, clinical study completion, and FDA review.

Future Outlook

Cellectar believes its cash balance as of December 31, 2024, is adequate to fund its basic budgeted operations into the fourth quarter of 2025, and the company is evaluating collaborations for iopofosine I 131 as a non-dilutive funding approach.

Management Comments

• James Caruso, president and CEO of Cellectar, stated that the company recently completed a productive meeting with the FDA that established a clear regulatory pathway for the accelerated approval of iopofosine I 131.
• James Caruso also mentioned that the company continues to evaluate inbound inquiries regarding a range of collaborations for iopofosine I 131, which they view as an attractive, non-dilutive funding approach.

Industry Context

Cellectar's focus on targeted radiotherapeutics aligns with the growing interest in precision medicine and the development of cancer treatments with improved efficacy and reduced off-target effects. The company's Phospholipid Drug Conjugate (PDC) delivery platform positions it to potentially compete with other companies developing targeted therapies.

Comparison to Industry Standards

• The 58.2% Major Response Rate (MRR) observed in the CLOVER-WaM study for Iopofosine I 131 compares favorably to existing treatments for relapsed/refractory Waldenström macroglobulinemia, where response rates can vary widely depending on the specific therapy and patient population.
• For example, BTK inhibitors like ibrutinib have shown ORRs in the range of 80-90% in WM, but the MRR is often lower, and resistance can develop over time.
• Cellectar's approach of using a targeted radiotherapeutic offers a different mechanism of action that could potentially overcome resistance to other therapies.
• Companies like Actinium Pharmaceuticals and Fusion Pharmaceuticals are also developing targeted radiotherapies, but Cellectar's PDC platform and focus on WM differentiate it from these competitors.

Stakeholder Impact

• Shareholders may be encouraged by the FDA alignment and clinical data, but concerned about the net loss.
• Employees may be affected by the company's focus on commercialization infrastructure.
• Patients with Waldenström macroglobulinemia could benefit from the potential approval of iopofosine I 131.
• The company's suppliers and partners may be impacted by the company's financial performance and development plans.

Next Steps

• Finalize confirmatory study design and regulatory pathway for potential FDA accelerated approval of iopofosine I 131.
• Complete full patient enrollment within 24 months of the first patient admitted to the study for iopofosine I 131.
• File an IND application in the first half of 2025 for CLR 121225.
• Initiate a Phase 1b/2a dose-finding study with CLR 121125 in triple-negative breast cancer.
• Evaluate timing for Phase 1 solid tumor studies.

Key Dates